Abstract 71P
Background
Despite durable responses achieved with Immune Checkpoint Inhibitors (ICIs), data about optimal duration of treatment, especially in the context of adverse events, remain scarce.
Methods
A systematic literature search was conducted in three electronic databases until July 2024. Studies referring to melanoma patients who ceased ICIs electively (i.e. due to complete response (CR), protocol completion or patient/physician’s wish) or due to treatment-limiting toxicities (TLTs) were selected. Relapse rates (RRs) post cessation, time to PD, rechallenge and disease control rate (DCR) after 2nd course were the main outcomes. Random-effects models were preferred, and subgroup and sensitivity analyses were conducted to investigate possible sources of heterogeneity.
Results
38 and 35 studies were included in qualitative and quantitative synthesis, respectively. From 2542 patients who discontinued treatment with ICIs, 495 experienced progression (n=34, RR 20.9%,95%CI 17.1–24.7%, I285%); higher rates were detected in patients with TLTs compared to elective disc. Mean time to PD was 14.26 months (n=18, mean time 14.26,95%CI 11.54–16.98,I293%) and was numerically longer in patients ceased for CR compared to patients with TLTs. Treatment duration before cessation was not associated with risk and time to relapse, while mucosal melanomas and non-CR as BOR during treatment led to increased risk for relapse and shorter time to PD compared to other histologic subtypes or CR. Rechallenge with ICI resulted in 57.3% DCR and 28.6% pooled CR rates (n=22, CR rate 28.6%, 95%CI 17.1–40.2, I268%). Subgroup analysis (type of ICI) and sensitivity analyses did not alter the results significantly. Table: 71P
n | Relapse Rate (%,95%CI) | n | Time to PD (mean,95% CI) | n | DCR rate (%,95%CI) | |
Overall population | 34 | 20.9 (17.1 – 24.7) | 18 | 14.2 (11.54 – 16.98) | 22 | 57.3 (43.9 – 70.6) |
Elective disc. | 27 | 15.9 (12.4 – 19.4) | 15 | 14.7 (11.77 – 17.82) | - | |
CR | 22 | 13.2 (10.5 – 16.0) | 14 | 15.8 (12.29 – 19.47) | - | |
TLTs | 14 | 25.9 (18.3 – 33.4) | 5 | 13.1 (9.69 – 16.54) | - |
Conclusions
Discontinuation of ICIs in patients without progression is possible. Outcomes to rechallenge with ICIs may differ depending on the reason for discontinuation, but remains a considerable option.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
U. Leiter-Stoppke: Financial Interests, Personal, Advisory Board, and speaker's honoraria: Sun Pharma, Regeneron, Sanofi; Financial Interests, Personal, Advisory Board: Pierre Fabre, Novartis, Almirall Hermal; Financial Interests, Institutional, Research Grant: MSD. L. Flatz: Financial Interests, Personal, Full or part-time Employment, Section Head of Dermato-oncology: University Hospital of Tübingen; Financial Interests, Personal, Stocks/Shares, Founder: Hookipa Pharma, Humion AG; Financial Interests, Personal, Ownership Interest, Founder: Abtherix GmbH, Schmelzberg GmbH; Financial Interests, Personal, Royalties, IP owner together with University of Zurich: Hookipa Pharma; Non-Financial Interests, Personal, Advisory Role: Philogen. T.M.S. Amaral: Financial Interests, Personal, Writing Engagement: CeCaVa, Medtrix; Financial Interests, Personal, Invited Speaker: BMS, Novartis, Pierre Fabre, Neracare; Financial Interests, Personal, Advisory Board: Delcath, Philogen; Financial Interests, Institutional, Funding: Novartis, Neracare, Sanofi, Skyline-Dx, Pascoe, MNI - Naturwissenschaftliches und Medizinisches Institut; Financial Interests, Institutional, Research Grant: Novartis, iFIT; Financial Interests, Institutional, Local PI: IO Biotech, MSD, University Hospital, Essen, Roche, BMS, BioNTech, Philogen, Pfizer, Immunocore, HUYA Bioscience, AstraZeneca, Agenus Inc., Regeneron; Financial Interests, Institutional, Coordinating PI: Unicancer; Non-Financial Interests, Personal, Member: Portuguese Society for Medical Oncology, ASCO; Other, Personal, Other, Clinical expert in the area of medical oncology: INFARMED - PT. All other authors have declared no conflicts of interest.
Resources from the same session
205P - Advancing pre-clinical functional tests with immune-responsive Precision Cut Bladder Tumor Slices (PCTS)
Presenter: Sarah Richtmann
Session: Poster Display session
Resources:
Abstract
206P - Characterisation of tumour-infiltrating lymphocytes (TILs) in liver metastases (LM) and primary tumour (PT) of microsatellite stable (MSS) colorectal cancers
Presenter: Yi Hua Low
Session: Poster Display session
Resources:
Abstract
207P - ZEB2 inhibition relieves TAMs-mediated immunosuppression in EGFR-TKI resistant NSCLC
Presenter: Yunhuan Liu
Session: Poster Display session
Resources:
Abstract
208P - Targeting pro-tumor TAMs to improve immune checkpoint response of advanced bladder cancer
Presenter: Marine Leblond
Session: Poster Display session
Resources:
Abstract
209P - Mapping the landscape of immune cells for optimal index calculation using AI-powered image analysis of multiplexed immunohistochemistry in breast cancer patients
Presenter: Patricia Nielsen
Session: Poster Display session
Resources:
Abstract
210P - Precision immuno-oncology strategies to overcome drug resistance in non-small cell lung cancer
Presenter: Heidi Haikala
Session: Poster Display session
Resources:
Abstract
211P - Single-cell characterization of differentiation trajectories and drug resistance features in gastric cancer with peritoneal metastasis
Presenter: Haoxin Peng
Session: Poster Display session
Resources:
Abstract
212P - YAP/TEAD4/SP1-induced VISTA expression as a tumor cell-intrinsic mechanism of immunosuppression in colorectal cancer
Presenter: Zhehui Zhu
Session: Poster Display session
Resources:
Abstract
214P - DNA-damaging therapies trigger transcriptome and metabolism changes in peripheral NK cells of SCLC patients
Presenter: Caterina de Rosa
Session: Poster Display session
Resources:
Abstract
215P - Differential spatial gene expression and clinicopathologic characteristics are associated with exceptional response to immune checkpoint inhibition in recurrent/metastatic head and neck cancer
Presenter: Niki Gavrielatou
Session: Poster Display session
Resources:
Abstract